Company news
Larimar Therapeutics, Inc. (NASDAQ:LRMR) news
Larimar Therapeutics, Inc. news releases on 6ix. Latest, Sep 29, 2026: Larimar Therapeutics Strengthens Executive Leadership with Appointment of John Harlow…
Press releases & updates
Larimar Therapeutics Strengthens Executive Leadership with Appointment of John Harlow as President and Chief Operating Officer
September 28, 2026
Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update
August 4, 2026
Larimar Therapeutics Reports Positive Open Label Data and Submission of First Module of Rolling BLA for Accelerated Approval of Nomlabofusp for Friedreich’s Ataxia
June 29, 2026
Larimar Therapeutics Announces Investor Event on the Nomlabofusp Program for Friedreich’s Ataxia
June 26, 2026
Larimar Therapeutics Reports First Quarter 2026 Financial and Business Update
May 14, 2026
Larimar Therapeutics Publishes Cross-Species Findings Supporting Skin as a Surrogate for the Measurement of Frataxin in Tissues Clinically Relevant to Friedreich’s Ataxia
April 30, 2026
Larimar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
March 19, 2026
Larimar Therapeutics to Participate in Upcoming Investor Conferences in March
March 4, 2026
Larimar Therapeutics Announces Proposed $75 Million Underwritten Public Offering
February 25, 2026
Larimar Therapeutics Announces Pricing of Upsized $100 Million Underwritten Public Offering
February 24, 2026
Larimar Therapeutics Announces FDA Breakthrough Therapy Designation for Nomlabofusp in FA and Reiterates Planned BLA Submission in June 2026
February 23, 2026
Larimar Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
December 18, 2025
Larimar Therapeutics Reports Third Quarter 2025 Financial Results
November 5, 2025
Larimar Therapeutics Announces Positive Data from Ongoing Long-term Open Label Study and Updates to Nomlabofusp Program for Friedreich’s Ataxia
September 29, 2025
Larimar Therapeutics Announces Conference Call on the Nomlabofusp Program for the Treatment of Friedreich’s Ataxia
September 28, 2025
Larimar Therapeutics Reports Second Quarter 2025 Financial Results
August 14, 2025
Larimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
July 31, 2025
Larimar Therapeutics Announces Proposed Underwritten Public Offering
July 29, 2025
Larimar Therapeutics Announces Pricing of Underwritten Public Offering
July 28, 2025
Larimar Therapeutics Publishes Nonclinical Data Supporting the Therapeutic Potential of Nomlabofusp in Patients with Friedreich’s Ataxia
July 8, 2025
Larimar Therapeutics Announces FDA Recommendations on Safety Database, and Other Details of Nomlabofusp BLA Submission for Friedreich’s Ataxia Program
June 23, 2025
Larimar Therapeutics Announces Regulatory Update Call on the Nomlabofusp Program for the Treatment of Friedreich’s Ataxia
June 20, 2025
Larimar Therapeutics Reports First Quarter 2025 Financial Results
April 30, 2025
Larimar Therapeutics Provides Nomlabofusp Development Update and Reports Fourth Quarter and Full Year 2024 Financial Results
March 24, 2025
Larimar Therapeutics to Present at the Leerink Partners Global Healthcare Conference
March 3, 2025
Larimar Therapeutics Announces Dosing of Adolescents in Nomlabofusp Pediatric Pharmacokinetic Run-In Study for Patients with Friedreich’s Ataxia
January 22, 2025
Larimar Therapeutics Announces Positive Initial Data from Ongoing Long-term Open Label Extension Study & Progress Across Nomlabofusp Program for Friedreich’s Ataxia
December 15, 2024
Larimar Therapeutics Reports Third Quarter 2024 Operating and Financial Results
October 29, 2024
Larimar Therapeutics Announces Three Poster Presentations at the Upcoming International Congress for Ataxia Research
September 18, 2024
Larimar Therapeutics Reports Second Quarter 2024 Operating and Financial Results
August 6, 2024
Larimar Therapeutics Selected by FDA to Participate in START Pilot Program for Nomlabofusp in Friedreich’s Ataxia
May 29, 2024
Larimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich’s Ataxia
May 19, 2024
Larimar Therapeutics Reports First Quarter 2024 Operating and Financial Results
May 8, 2024
Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp Development
March 13, 2024
Larimar Therapeutics Announces the Dosing of the First Patient in Long-term Open Label Extension Study for Nomlabofusp in Patients with Friedreich’s Ataxia
March 10, 2024
Larimar Therapeutics Announces Pricing of Underwritten Public Offering of Common Stock
February 13, 2024
Larimar Therapeutics Reports Positive Top-line Data from Phase 2 Dose Exploration Study from 25 mg and 50 mg Cohorts of Nomlabofusp in Patients with Friedreich’s Ataxia
February 11, 2024
Larimar Therapeutics Reports Third Quarter 2023 Operating and Financial Results
November 13, 2023
Larimar Therapeutics Appoints Dr. Jeffery W. Sherman to its Board of Directors
October 2, 2023
Larimar Therapeutics Reports Second Quarter 2023 Operating and Financial Results
August 9, 2023
Larimar Therapeutics Receives FDA Clearance to Proceed to 50 mg Cohort in CTI-1601’s Phase 2 Friedreich's Ataxia Trial and to Initiate Open Label Extension Trial
July 24, 2023
Larimar Therapeutics Appoints Dr. Rusty Clayton as Chief Medical Officer
July 16, 2023
Larimar Therapeutics Reports Preliminary Top-line Data from Phase 2 Trial’s 25 mg Cohort Showing Increases in Frataxin Levels in Patients with Friedreich’s Ataxia and First Quarter 2023 Financial Results
May 14, 2023
Larimar Therapeutics Reports Fourth Quarter and Full Year 2022 Operating and Financial Results
March 13, 2023
Larimar Therapeutics Appoints Dr. Gopi Shankar as Chief Development Officer
February 6, 2023
Larimar Therapeutics Reports Third Quarter 2022 Operating and Financial Results
November 9, 2022
Larimar Therapeutics Announces Issuance of U.S. Patent Providing Composition of Matter Protection for CTI-1601
October 19, 2022
Larimar Therapeutics Announces Oral and Poster Presentations at the Upcoming International Congress for Ataxia Research
October 18, 2022
Larimar Therapeutics Announces Closing of Underwritten Offering and Full Exercise of Option to Purchase Additional Shares
September 15, 2022
Larimar Therapeutics Announces FDA Clearance to Initiate the 25 mg Cohort of a Phase 2 Dose Exploration Trial of CTI-1601 in Friedreich’s Ataxia Patients
September 13, 2022